Gastrointestinal Cancer

Trial Add-Aspirin Trial
Cancer Type Bowel Cancer, Gastrointestinal, Genitourinary, Miscellaneous, Oesophageal Cancer, Prostate Cancer, Stomach Cancer, and Non-specific
Hospital(s) Belfast City Hospital
Information

A Phase III, Double-Blind, Placebo-Controlled Randomised Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival after Primary Therapy in Common Non-Metastatic Solid Tumours

Click Here to view CancerHelpUK trial summary
Trial BALLAD UK
Cancer Type Bowel Cancer and Gastrointestinal
Hospital(s) Belfast City Hospital
Information

A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma

Click Here to view CancerHelpUK trial summary
Trial CHALLENGE
Cancer Type Bowel Cancer and Gastrointestinal
Hospital(s) Belfast City Hospital
Information

A phase III study of the impact of a physical activity programme on disease-free survival in patients with high risk stage II or stage III colon cancer: A randomised controlled trial

Trial COSMIC 312
Cancer Type Gastrointestinal
Hospital(s) Belfast City Hospital
Information

A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

Trial CReST 2
Cancer Type Bowel Cancer and Gastrointestinal
Hospital(s) Ulster Hospital
Information

Colorectal Stenting Trial 2 – Uncovered and Covered Endoluminal Stenting in the acute management of obstructing colorectal cancer in the palliative setting

Click Here to view CancerHelpUK trial summary
Trial ICHOR
Cancer Type Gastrointestinal, Oesophageal Cancer, and Stomach Cancer
Hospital(s) Belfast City Hospital
Information

Investigation of Circulating Haematological Biomarkers in Cancer

Trial MK3475-937
Cancer Type Gastrointestinal
Hospital(s) Belfast City Hospital
Information

A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)

Trial MK3475-966
Cancer Type Gastrointestinal
Hospital(s) Belfast City Hospital
Information

A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma

Trial OCCAMS
Cancer Type Gastrointestinal and Oesophageal Cancer
Hospital(s) Belfast City Hospital
Information

Multicentre Study to determine Predictive and Prognostic Biomarkers and Therapeutic Targets for Oesophageal and Junctional Adenocarcinoma including whole genome sequencing

Click Here to view CancerHelpUK trial summary
Trial PLATFORM
Cancer Type Gastrointestinal, Oesophageal Cancer, and Stomach Cancer
Hospital(s) Belfast City Hospital
Information

PLAnning Treatment For Oesophago-Gastric Cancer: a Randomised Maintenance Therapy Trial

Trial Precision-Panc
Cancer Type Gastrointestinal and Pancreatic Cancer
Hospital(s) Belfast City Hospital
Information

Master Protocol Personalising Treatment For Pancreatic Cancer

Trial PRIMUS-001
Cancer Type Gastrointestinal and Pancreatic Cancer
Hospital(s) Belfast City Hospital
Information

An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation

Trial PROMETCO
Cancer Type Bowel Cancer and Gastrointestinal
Hospital(s) Altnagelvin Hospital
Information

A real world prospective cohort study in the management of metastatic colorectal cancer: a clinical and patient perspective

Trial SCOPE 2
Cancer Type Gastrointestinal and Oesophageal Cancer
Hospital(s) Belfast City Hospital
Information

A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET)